Publications & press

News & updates

Dr Glen Chertow Interview

Video: Interview with Dr. Glenn Chertow

pipeline - olc

Video: Our Lead Asset (Oxylanthanum Carbonate)

AJN: High Phosphate-Binding Capacity of oxylanthanum carbonate with a Low Medication Volume: Comparison with Commercially Available Phosphate Binders

Two Way Randomized Crossover Study cover

Two-Way Randomized Crossover Study to Establish Pharmacodynamic Bioequivalence Between oxylanthanum carbonate and Lanthanum Carbonate

vaEvaluation of UNI-494 in Acute Kidney Injury Treatment Efficacy When Administered After Ischemia-Reperfusion in a Rat Model cover

EC Pharmacology and Toxicology: Evaluation of UNI-494 in Acute Kidney Injury Treatment Efficacy When Administered After Ischemia-Reperfusion in a Rat Model

Pharmaceutical Chemistry Journal: Systemic Absorption of Oxylanthanum Carbonate is Minimal in Preclinical Models

study design

Combination Oxylanthanum Carbonate and Tenapanor Synergistically Lowers Urinary Phosphate Excretion in Rats

Phase 1 Study Design Part 1

UNI-494 Phase I Safety, Tolerability, and Pharmacokinetics

Intravenous UNI-494 Slows the Progression or Halts/Reverses Acute Kidney Injury When Administered After Ischemia/Reperfusion in Rats

Effects of Oxylanthanum Carbonate in Patients Receiving Maintenance Hemodialysis with Hyperphosphatemia

Figure 3. Histological Image Where the Nature of the Proximal Tubule Injury Is Pointed with Arrows

Oral Administration of UNI-494 Ameliorates Acute Kidney Injury in a Rat Model of Delayed Graft Function

Figure 1. Study Design – OLC + Tenapanor Combo Study

Enhanced Urinary Phosphorous Reduction: Comparative Study of Oxylanthanum Carbonate and Tenapanor in Rats

Figure 1. The Primary Mode of Action of UNI-494 in the Treatment of Acute Kidney Injury

UNI-494 Phase I Safety, Tolerability and Pharmacokinetics: Trial in Progress

Figure 1. Number of Pills to Bind 1g of Phosphate by Binder – Estimated with Dose

Oxylanthanum Carbonate for Hyperphosphatemia in ESKD: Tolerability Trial in Progress

Figure 1. Proportion of Patients Non-Adherent to Phosphate Binder Therapy by Study

Renal Dietitians Perceive Phosphate Binder and Low Phosphorus Diet Non-Compliance as Top Reasons for Above Target Serum Phosphorus Concentrations

Figure 1. Study Schematic

Two-Way Crossover Study to Establish Pharmacodynamic Bioequivalence Between OxylanthanumCarbonate and Lanthanum Carbonate

About Unicycive

Video: About Unicycive

Figure 1. The Proposed Primary Mode of Action of UNI-494 in the Treatment of AKI

UNI-494 Phase I Safety, Tolerability and Pharmacokinetics: Trial in Progress

Figure 3: Mean (±SE) Urine Phosphorus/Creatinine Ratios 1 Among Renazorb, Sevelamer, and Control Groups of Rats (On Treatment)

Intravenous Administration of UNI-494 Ameliorates Acute Kidney Injury in Rat Model of Delayed Graft Function

Unmet Need video thumb

Video: An Unmet Need in Hyperphosphatemia